Reuters logo
16 天内
Novartis receives EU approval for Cosentyx label update
2017年7月6日 / 凌晨5点32分 / 16 天内

Novartis receives EU approval for Cosentyx label update

1 分钟阅读

ZURICH, July 6 (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday. (Reporting by Silke Koltrowitz)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below